Pre-made Oleclumab benchmark antibody ( Whole mAb, anti-NT5E/CD73 therapeutic antibody, Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-394
Pre-Made Oleclumab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Oleclumab (INN; development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Oleclumab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute|
|Conditions Active||Non-small cell lung cancer;Ovarian cancer;Breast cancer;Pancreatic cancer;Bladder cancer;Solid tumours|